SV

Street Verdict

Analyst Scorecard

A record of what JM Financial Analysis said publicly, with the source. Not advice.

“JM Financial maintains a 'Buy' rating on Sun Pharmaceutical Industries with a revised target price of Rs 2,025 for a one-year period. This positive outlook is driven by expected growth exceeding 10% over FY25-28, anchored by the upcoming Phase 3 data release for Ilumya in 2H CY25, the launch of Leqselvi in 2QFY26, and strategic acquisitions enhancing its oncology portfolio.”

JM Financial Analysis’s track record (trackable calls only): 213 graded calls · 95% CI 41–54%

Sun Pharmaceutical IndustriesBullishCalled 26 May 2025Graded 26 May 2026
Verdict:MISS

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹2,025, as stated.

Window: 12 months, the time frame the call states ("one-year").

Neither the target ₹2,025 was reached on a close by the end of the window. Miss.

The grader’s working: R4 TARGET_CALL: entered ₹1683.4 on 2025-05-27 (next trading session's close); neither target nor stop reached by window end 2026-05-26. Window 365 days — rule H1: the quote states "one-year".

Tracking Sun Pharmaceutical Industries since this call

1-year tracking window
Read the original articleSee JM Financial Analysis’s full track record